"A new type of malaria drug successfully cured more than 97% of people that were given it in a clinical trial, outperforming existing treatments. The drug, ganaplacide-lumefantrine (GanLum), kills malarial parasites in a different way from existing treatments, many of which rely on the plant-derived compound artemisinin. As such, it could circumvent the partial resistance to artemisinin emerging among parasites in southeast Asia and several African countries."
"The shutdown of the US government, which shuttered science agencies, halted grant operations and left tens of thousands of federal scientists without paychecks, is over after lasting a record-breaking 43 days. Under the terms of a deal between lawmakers in Congress, federal researchers will be paid what they would have earned during the furlough, and those who were laid off will be rehired - at least for now."
Global greenhouse-gas emissions are still rising, though some analyses indicate they may peak around 2030. A new antimalarial combination, ganaplacide-lumefantrine (GanLum), cured over 97% of trial participants and operates via a mechanism distinct from artemisinin, offering a potential solution to partial artemisinin resistance in Southeast Asia and parts of Africa; regulatory approval could come within 12–18 months as the first new antimalarial class in over 25 years. A 43-day US federal shutdown halted science agencies, paused grant operations, left many federal scientists unpaid, and will require extensive rescheduling and rehiring to restore research activity.
Read at Nature
Unable to calculate read time
Collection
[
|
...
]